BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35533704)

  • 21. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
    Valli N; Catargi B; Ronci N; Vergnot V; Leccia F; Ferriere JM; Chene G; Grenier N; Laurent F; Tabarin A
    Eur J Endocrinol; 2001 Apr; 144(4):401-8. PubMed ID: 11275951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P; Orsolini F; Benelli E; Agretti P; Vitti P; Di Cosmo C; Tonacchera M
    Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.
    Reincke M; Nieke J; Krestin GP; Saeger W; Allolio B; Winkelmann W
    J Clin Endocrinol Metab; 1992 Sep; 75(3):826-32. PubMed ID: 1517373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study.
    Di Dalmazi G; Vicennati V; Pizzi C; Mosconi C; Tucci L; Balacchi C; Cosentino ER; Paolisso P; Fanelli F; Gambineri A; Pelusi C; Repaci A; Garelli S; Galiè N; Borghi C; Golfieri R; Pagotto U
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32413902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas.
    Reimondo G; Allasino B; Bovio S; Saba L; Ardito A; Angeli A; Terzolo M
    J Endocrinol Invest; 2011 Jan; 34(1):e1-5. PubMed ID: 20634637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACTH following overnight dexamethasone suppression can be used in the verification of autonomous cortisol secretion in patients with adrenal incidentalomas.
    Puvaneswaralingam S; Kjellbom A; Lindgren O; Löndahl M; Olsen H
    Clin Endocrinol (Oxf); 2021 Feb; 94(2):168-175. PubMed ID: 33108675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
    Araujo-Castro M; Mínguez Ojeda C; Sánchez Ramírez MN; Gómez Dos Santos V; Pascual-Corrrales E; Fernández-Argüeso M
    Endocrine; 2022 Oct; 78(1):142-150. PubMed ID: 35751779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M; García Cano AM; Escobar-Morreale HF; Valderrabano P
    Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas.
    Sbardella E; Minnetti M; D'Aluisio D; Rizza L; Di Giorgio MR; Vinci F; Pofi R; Giannetta E; Venneri MA; Vestri A; Morelli S; Lenzi A; Isidori AM
    Eur J Endocrinol; 2018 May; 178(5):501-511. PubMed ID: 29510982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas Adrenal Diseases Group of the Spanish Society of Endocrinology and Nutrition.
    Araujo-Castro M; Iturregui Guevara M; Calatayud Gutiérrez M; Parra Ramírez P; Gracia Gimeno P; Hanzu FA; Lamas Oliveira C
    Endocrinol Diabetes Nutr (Engl Ed); 2020; 67(6):408-419. PubMed ID: 32349941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autonomous cortisol secretion : Laboratory artifact or disease?].
    Riester A; Beuschlein F
    Internist (Berl); 2022 Jan; 63(1):18-24. PubMed ID: 34709420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: a study of 709 cases.
    Brox-Torrecilla N; García Cano AM; Valderrábano P; Quintero Tobar A; Escobar-Morreale HF; Araujo-Castro M
    Endocrine; 2023 Sep; 81(3):484-491. PubMed ID: 37212980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different patterns of steroid secretion in patients with adrenal incidentaloma.
    Terzolo M; Osella G; Alì A; Borretta G; Magro GP; Termine A; Paccotti P; Angeli A
    J Clin Endocrinol Metab; 1996 Feb; 81(2):740-4. PubMed ID: 8636297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between adrenal adenoma size, autonomous cortisol secretion and metabolic derangements.
    Bleier J; Pickovsky J; Apter S; Fishman B; Dotan Z; Tirosh A; Shlomai G
    Clin Endocrinol (Oxf); 2022 Mar; 96(3):311-318. PubMed ID: 34877671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular complications of mild autonomous cortisol secretion.
    Aresta C; Favero V; Morelli V; Giovanelli L; Parazzoli C; Falchetti A; Pugliese F; Gennari L; Vescini F; Salcuni A; Scillitani A; Persani L; Chiodini I
    Best Pract Res Clin Endocrinol Metab; 2021 Mar; 35(2):101494. PubMed ID: 33814301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma.
    Fernández-Real JM; Engel WR; Simó R; Salinas I; Webb SM
    Clin Endocrinol (Oxf); 1998 Jul; 49(1):53-61. PubMed ID: 9797847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk.
    Di Dalmazi G; Fanelli F; Zavatta G; Ricci Bitti S; Mezzullo M; Repaci A; Pelusi C; Gambineri A; Altieri P; Mosconi C; Balacchi C; Golfieri R; Cosentino ER; Borghi C; Vicennati V; Pasquali R; Pagotto U
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5519-5528. PubMed ID: 31381072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are comorbidities of patients with adrenal incidentaloma tied to sex?
    Puglisi S; Barač Nekić A; Morelli V; Alessi Y; Fosci M; Pani A; Zibar Tomsic K; Palmieri S; Ferraù F; Pia A; Chiodini I; Kastelan D; Reimondo G; Terzolo M
    Front Endocrinol (Lausanne); 2024; 15():1385808. PubMed ID: 38808113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.
    Araujo-Castro M; Parra Ramírez P; Robles Lázaro C; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.